The Supreme Court unanimously ruled in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., No. 24-889, that a branded pharmaceutical company alleging induced patent infringement against a generic manufacturer must plausibly plead that the generic actively encouraged infringing use of its product based on specific “statements designed to stimulate” infringement, not merely that physicians could conceivably read the generic’s label and other communications as instructions to infringe. The decision reaffirms the viability of the skinny label carve-out pathway for generics and may create significant new hurdles for branded companies seeking to plead and prove inducement.
Amarin’s Vascepa is a prescription fish oil drug with two distinct approved uses. Initially, Vascepa had just one approved use: treating severe hypertriglyceridemia (called the “SH indication” in the decision). Subsequently, Amarin secured FDA approval for a second indication: reducing cardiovascular risk in certain high-risk patients taking statins (called the “CV indication”). Amarin obtained multiple patents on the CV indication (the “CV patents”), expiring in 2033. Notably, when Amarin added the CV indication to its label, it removed a preexisting warning that the drug’s effects in patients with cardiovascular risk factors were unknown (termed the “CV Limitation of Use” in the Court’s opinion).
When Hikma sought FDA approval for a generic version of the drug, it used the Hatch-Waxman Act’s “section viii” carve-out provision to omit the CV indication from its label. That produced a skinny label: an FDA-recognized approach that lets generics seek approval on unpatented uses while removing patented indications from their product’s label, thereby potentially avoiding patent litigation on those patented indications. This approach is a limited exception to the general rule that a generic’s label must be essentially identical to the brand’s in order to receive FDA approval under the abbreviated new drug application (ANDA) pathway. Consistent with that general rule, Hikma’s label omitted the CV Limitation of Use, which Amarin itself had likewise removed from Vascepa’s label when it added the CV indication.
Amarin sued Hikma for induced infringement of the CV patents despite Hikma’s carve-out. Amarin’s theory was that Hikma’s press releases describing the product as “generic Vascepa,” combined with website content and certain statements remaining in Hikma’s label after the carve-out, would signal to physicians that the drug could be used for Vascepa’s CV indication, effectively inducing infringement of the CV patents. As to the remaining label statements, Amarin alleged that Hikma’s skinny label described a clinical study using the product in combination with statins, thus encouraging doctors to treat the CV indication (which required coadministration with statins). Amarin also alleged that Hikma’s omission of the CV Limitation of Use, which Amarin removed from the label only once the CV indication was added, would further point to use of Hikma’s product for the CV indication.
The U.S. District Court for the District of Delaware dismissed Amarin’s complaint, concluding that Amarin had not plausibly alleged active inducement. The U.S. Court of Appeals for the Federal Circuit reversed, finding that the combination of Hikma’s label, marketing materials, and communications could plausibly lead a physician to prescribe the generic for the patented CV indication, thus inducing infringement. The Supreme Court granted certiorari and reversed the Federal Circuit.
Writing for a unanimous Court, Justice Ketanji Brown Jackson explained that a patent owner pleading induced infringement in the skinny label context must plausibly allege that the generic manufacturer actively encouraged infringing uses. Per the Court, patentees must identify “statements designed to stimulate others” to infringe, rather than “‘vague’ language ‘combined with speculation about how [others] may act.’” That distinction proved outcome-determinative for Amarin. The Federal Circuit had applied the wrong test by asking whether doctors could plausibly interpret Hikma’s label and other communications as inducing infringement, rather than examining whether Hikma itself had affirmatively encouraged such use.
Walking through Hikma’s conduct, the Court explained that the skinny label itself omitted the patented indication, while Hikma’s press releases and website statements were not compelling evidence of active encouragement. The connection between those statements and any genuine encouragement of infringing prescriptions was too attenuated to survive dismissal. Per Jackson, these allegations amounted to “‘vague’ statements ‘combined with speculation’” and were therefore insufficient to make inducement plausible.
The Court was likewise unmoved by the Hikma label’s mention of coadministration with statins, which appeared pursuant to statutory requirements (“an ‘obvious alternative explanation’” for their inclusion) rather than to actively encourage infringement. And because inducement requires “affirmative ‘statements or actions,’” rather than mere omissions, Hikma’s failure to reincorporate the CV Limitation of Use could not plausibly support Amarin’s inducement claim.
Importantly, the Court also rejected Hikma’s more aggressive counter argument, which would have required express statements of inducement to sustain a claim. The Court clarified that implicit encouragement may suffice, so long as the inducement is clear and affirmative to the relevant audience. The ruling therefore suggests a middle ground, raising the pleading bar above what the Federal Circuit required, while declining to categorically immunize generic manufacturers from induced infringement liability simply because they use a skinny label.
The Supreme Court’s ruling arguably heightens the standard for pleading inducement by a skinny label by shifting emphasis from what a doctor plausibly might do upon reading the generic’s labeling and other statements, to whether the generic’s statements were specifically designed to elicit infringement. This approach deemphasizes an objective assessment of how a doctor might act based on the generic’s statements in favor of a seemingly subjective assessment of whether the generic’s statements were specifically intended to prompt infringement. Marshaling facts to support such allegations may be challenging for patentees, particularly at the pleadings stage, before any discovery occurs.
Industry participants closely monitored the recent GlaxoSmithKline v. Teva series of cases, which culminated in the Federal Circuit’s conclusion that sufficient evidence supported a judgment of inducement despite a skinny label, based in part on statements outside the label. Since then, conventional wisdom has been that generics should carefully control their commercial communications to minimize risk of inducement when using a skinny label strategy. Increased caution from generics may compound patentees’ challenges in pleading inducement in borderline cases, particularly under the strict standards announced in Hikma v. Amarin. There has been an increase in Rule 12 motions challenging inducement pleadings in Hatch-Waxman cases, even outside the skinny label context; the Supreme Court’s ruling in Hikma v. Amarin may spur even more such motion practice, particularly in carve-out cases.
The Amarin Court’s decision to immunize statements included in a label pursuant to statute (i.e., the Hikma label’s reference to coadministration with statins in a clinical trial) may also be significant. Some earlier cases finding inducement despite a skinny label may best be described as “failed carve-out” cases, i.e., the generic sought to remove the patented indication from its label, but certain information that could not be eliminated, like information in the label’s clinical trials section, still supported inducement. Patentees may find it more difficult to advance a “failed carve-out” argument if the generic can argue that any allegedly inducing statements that remain post-carve-out are required by statute and/or FDA regulation and therefore cannot support an inducement theory under Amarin.
On the positive side for branded companies, Amarin unequivocally endorses an “implicit inducement” theory and rejects Hikma’s argument that only express statements by a generic instructing doctors to infringe can support inducement. This means combinations of evidence from various sources may be used to support inducement by implication, with guidance from Amarin as to what types of statements might be too vague to support an inducement claim.
The enforcement picture may be shifting for inducement claims in the skinny label context. Branded companies may need a record of concrete, physician-directed promotional conduct if a skinny label induced infringement suit is likely to survive a motion to dismiss. They may also find it more difficult to rely on statements remaining in the generic’s label following a carve-out to support inducement.
These changes have practical downstream effects on how companies approach pre-litigation investigation, what they monitor post-launch, and how they allocate enforcement resources. Tracking a generic’s commercial activities and prescriber-facing communications may become a more central part of a branded company’s strategy, particularly if courts apply more stringent requirements for pleading inducement based on product labeling, as Hikma v. Amarin seems to dictate. In particular, pre-launch surveillance and post-launch monitoring of generic promotional activity may help craft a persuasive “implicit inducement” strategy, given the Amarin Court’s clear statements leaving the door open to such an approach.
On the patent side, method-of-use claims protecting a single indication may provide even thinner coverage than previously thought. And patentees may not be able to rely as much on information appearing outside the indications section of the label to prove inducement when such information must be included in the generic’s label by statute, potentially compromising many branded companies’ inducement strategies.
Therefore, if method-of-use claims represent the primary protection for a commercially significant indication, consider assessing what other layers of patent or regulatory exclusivity are possible. For example, composition patents, formulation patents, and regulatory exclusivities (orphan drug, pediatric, and new chemical entity) may carry relatively more weight if method-of-use patent enforcement requires clearing a higher evidentiary threshold.
For innovative companies at earlier stages, consider revisiting how claim scope is structured, prosecution timelines, and exclusivity layering in relation to commercial runway. Method-of-use patents protect important innovations and may be most effective as part of a layered portfolio rather than as the sole line of defense.
In sum, branded companies should consider reassessing not only their inducement theories, but also their prosecution and regulatory strategies in view of the Court’s Hikma v. Amarin decision.